Почетна › Рак јајника › Пенсилванија › Pittsburgh
Kliničke studije za Рак јајника u gradu Pittsburgh, PA
32 studija za Рак јајника traži učesnike na lokacijama u gradu Pittsburgh i okolini (u krugu od oko 30 milja). Otvorite studiju da biste videli ko može da učestvuje i kako kontaktirati tim studije.
Zvanični tekst studije (na engleskom)
Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
Тражи се учесникФаза 2/3
- UPMC Hillman Cancer Center, Pittsburgh
- UPMC-Passavant Hospital, Pittsburgh
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Тражи се учесникФаза 2
- UPMC-Magee Womens Hospital, Pittsburgh
- UPMC Hillman Cancer Center, Pittsburgh
- UPMC-Passavant Hospital, Pittsburgh
- и још 3
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Тражи се учесникФаза 3
- Allegheny Health Network West Penn Hospital ( Site 0099), Pittsburgh
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Тражи се учесникФаза 3
- AHN West Penn Hospital ( Site 0051), Pittsburgh
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Тражи се учесникФаза 2
- University of Pittsburgh Medical Center, Magee-Womens Hospital, Pittsburgh
- West Penn Hospital of Allegheny Health Network, Pittsburgh
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Тражи се учесник
- Allegheny General Hospital, Pittsburgh
- UPMC-Magee Womens Hospital, Pittsburgh
- West Penn Hospital, Pittsburgh
- и још 6
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Тражи се учесникФаза 1/2
- Allegheny Health Network, Pittsburgh
Distance-Based Exercise to Preserve Function and Prevent Disability
Тражи се учесник
- UPMC-Magee Womens Hospital, Pittsburgh
- UPMC Hillman Cancer Center, Pittsburgh
- UPMC-Passavant Hospital, Pittsburgh
- и још 2
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
Тражи се учесникФаза 1
- University of Pittsburgh Medical Center, Pittsburgh
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Тражи се учесникФаза 1
- UPMC, Pittsburgh
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Тражи се учесникФаза 1/2
- University of Pittsburgh Medical Center, Pittsburgh
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Тражи се учесникФаза 2
- West Penn Hospital /ID# 276028, Pittsburgh
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Тражи се учесникФаза 3
- University of Pittsburgh Cancer Institute Cancer Services, Pittsburgh
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
Тражи се учесникФаза 2
- Western Pennsylvania Gynecologic Oncology /ID# 278632, Pittsburgh
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Тражи се учесникФаза 1/2
- Research Site, Pittsburgh
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Тражи се учесникФаза 1
- UPMC Hillman Cancer Center, Pittsburgh
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Тражи се учесникФаза 1/2
- University of Pittsburgh Medical Center, Pittsburgh
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Тражи се учесникФаза 1
- Research Site, Pittsburgh
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Тражи се учесникФаза 1/2
- Allegheny Health Network, Pittsburgh
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Тражи се учесникФаза 3
- AHN West Penn Hospital, Pittsburgh
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Тражи се учесникФаза 1/2
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Тражи се учесникФаза 2
- 127, Pittsburgh
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Тражи се учесникФаза 2
- Allegheny Health Network, Pittsburgh
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
Тражи се учесникФаза 2
- UPMC Magee-Women's Hospital, Pittsburgh
CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer
Тражи се учесникФаза 1
- Magee-Womens Research Institute / UPMC Magee Womens Hospital, Pittsburgh
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
Тражи се учесникФаза 2
- University of Pittsburgh Medical Center, Pittsburgh
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
Тражи се учесникФаза 1
- UPMC Hillman Cancer Center, Pittsburgh
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
Тражи се учесникФаза 2
- Allegheny Health Network West Penn Hospital /ID# 272267, Pittsburgh
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Тражи се учесникФаза 1/2
- University of Pittsburgh Medical Center, Pittsburgh
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Тражи се учесникФаза 3
- West Penn Hospital, Pittsburgh
- Jefferson Hospital, Jefferson Hills · 11 ми удаљено
- Forbes Hospital, Monroeville · 11 ми удаљено
- и још 1
Heated Versus Aerosol-based Laparoscopic Chemotherapy for Cancer That Has Spread to the Peritoneum (Abdominal Lining)
Тражи се учесникФаза 2
- Allegheny Health Network West Penn Hospital, Pittsburgh
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
Тражи се учесникФаза 1
- UPMC Hillman Cancer Center, Pittsburgh
Studije za Рак јајника u drugim gradovima
- Houston, TX90 студија
- New York City, NY75 студија
- Boston, MA62 студија
- Los Angeles, CA53 студија
- Nashville, TN50 студија
- Arlington, VA47 студија
- Philadelphia, PA47 студија
- Columbus, OH39 студија
- St. Louis, MO37 студија
- Chicago, IL36 студија
- San Antonio, TX33 студија
- Dallas, TX31 студија
Ostale studije u gradu Pittsburgh
- Немалоклетни карцином плућа47 студија
- Рак (све врсте)42 студија
- Рак дојке42 студија
- Колоректални карцином31 студија
- Метастатски карцином31 студија
- Меланом31 студија
- Карцином ендометријума24 студија
- Рак плућа24 студија
- Плоскоклеточни карцином главе и врата23 студија
- Рак простате23 студија
- Депресија22 студија
- Шлог21 студија
Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.